New patent is granted with the title of “Treatment of Patients Diagnosed with Pancreatic Ductal Adenocarcinoma Using Monoclonal Antibodies Against the EGFR” in Russia with the validity until 27 Jul 2033.
Adelaide, South Australia (June 20, 2017) – Innokeys Pte Ltd attended ANZCHOG 2017 – a conference which is organized annually by the…
New marketing authorization for indication locally advanced unresectable or metastatic pancreatic cancer is approved in Myanmar by the Myanmar FDA. This indication…
Speakers: 1. dr. Raymond King-Yin TSANG, MBChB, MS, FRCSEd, FRCSEd(ORL), FHKCORL, FHKAM(Otorhinolaryngology) as Head of the Division of Otorhinolaryngology of the…
Tokyo, Japan (April 25, 2013) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that the first patient has been enrolled in…
On 24 Sep 2019, Cambodia Ministry of Health approved new marketing authorization for indication locally advanced unresectable or metastatic pancreatic cancer for…